Accueil>>Signaling Pathways>> Membrane Transporter/Ion Channel>> Potassium Channel>>Almokalant (H 234/09)

Almokalant (H 234/09)

Catalog No.GC32673

Almokalant (H 234/09) est un médicament antiarythmique de classe III, agit comme un inhibiteur des canaux potassiques et inhibe une composante spécifique (Ikr) du courant redresseur retardé dépendant du temps K+.

Products are for research use only. Not for human use. We do not sell to patients.

Almokalant (H 234/09) Chemical Structure

Cas No.: 123955-10-2

Taille Prix Stock Qté
250mg Please Inquire Please Inquire
500mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com


Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Almokalant is a class III antiarrhythmic drug, acts as a potassium channel blocker, and inhibits a specific component (Ikr) of the time-dependent delayed rectifier K+ current.

Almokalant is a class III antiarrhythmic drug, acts as a potassium channel blocker, and inhibits a specific component (Ikr) of the time-dependent delayed rectifier K+ current[1].

Almokalant (125 μmol/kg, p.o.) induces cardiovascular defects, orofacial clefts, and tail defects in pregnant rats, after administration on Day 11. Almokalant also causes in pregnant rats[1].

[1]. Wellfelt K, et al. Teratogenicity of the class III antiarrhythmic drug almokalant. Role of hypoxia and reactive oxygen species. Reprod Toxicol. 1999 Mar-Apr;13(2):93-101.

Avis

Review for Almokalant (H 234/09)

Average Rating: 5 ★★★★★ (Based on Reviews and 19 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Almokalant (H 234/09)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.